Pomalidomide-PEG1-C2-N3

Background Introduction

Pomalidomide-PEG1-C2-N3 is a specialized E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications, such as the development of PROTACs (Proteolysis Targeting Chimeras). This compound leverages the well-established cereblon (CRBN)-recruiting capabilities of pomalidomide, combined with a versatile PEG-based linker and a terminal azide (N3) functional group. This modular structure makes it an ideal chemical building block for researchers developing next-generation protein degradation tools.

Mechanism

Pomalidomide acts as an E3 ligase ligand, specifically binding to the cereblon (CRBN) component of the E3 ubiquitin ligase complex. The PEG1-C2 linker enhances solubility and provides spatial flexibility, facilitating optimal ternary complex formation in PROTAC designs. The terminal azide (N3) serves as a bioorthogonal reactive handle, enabling efficient click chemistry conjugation to various targeting ligands. When incorporated into a PROTAC molecule, Pomalidomide-PEG1-C2-N3 enables the recruitment of the CRBN E3 ligase to a protein of interest, triggering ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Pomalidomide-PEG1-C2-N3 is widely used in the field of chemical biology and drug discovery for the synthesis of CRBN-based PROTACs and molecular glues. Its terminal azide group facilitates rapid and efficient bioconjugation with alkyne-containing ligands through click chemistry. Key applications include: construction of heterobifunctional degraders to target disease-related proteins, creation of chemical probes to study protein degradation pathways, and rapid prototyping of new protein degradation modalities. Its modularity makes it compatible with high-throughput library screening and medicinal chemistry optimization, accelerating the discovery of novel protein degraders.

Pomalidomide-PEG1-C2-N3 is an E3 Ligase Ligand-Linker Conjugate designed for the development of PROTACs, facilitating targeted protein degradation by bridging target proteins to E3 ubiquitin ligases. The following provides a detailed description of this molecule.

Linker: The linker in this molecule is a PEG1-C2 moiety, characterized by its short length and moderate flexibility. It provides a balance between rigidity and flexibility, allowing optimal spatial orientation, and is non-cleavable, ensuring stable conjugation throughout the degradation process.

Ligand: The ligand component is based on pomalidomide, a thalidomide analog known for its potent binding affinity to the cereblon E3 ubiquitin ligase. Its structural characteristics enhance the specificity and efficiency of target protein ubiquitination.

Reactive Site: The reactive site features an azide group (N3), which is well-suited for click chemistry reactions such as the copper-catalyzed azide-alkyne cycloaddition (CuAAC). This site facilitates robust and selective coupling with alkyne-functionalized target protein ligands.

Recommended Target Protein Ligand: The recommended warhead for this molecule is an alkyne-modified ligand, which offers efficient and selective conjugation through click chemistry. This approach enhances the modularity of PROTAC design, allowing researchers to tailor degradation profiles for specific proteins of interest, thus advancing studies in targeted therapy and protein homeostasis.